Role of lenalidomide in the treatment of myelodysplastic syndromes

Seminars in Oncology

Volumn 38, Issue 5, 2011, Pages 648-657

  Komrokji, Rami S ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; LENALIDOMIDE; PLACEBO;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLEEDING; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANEMIA, MACROCYTIC; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; THALIDOMIDE; THROMBOCYTOPENIA;

EID: 80053177581     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.015     Document Type: Article

References (54)

1. R.S. Komrokji, L. Zhang, and J.M. Bennett Myelodysplastic syndromes classification and risk stratification Hematol Oncol Clin North Am 24 2010 443 457
2. J.M. Bennett, and A.F. List Disparities in criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS) ASH Annual Meeting Abstracts 106 2005 2535
3. M. Melchert, and A.F. List Management of RBC-transfusion dependence Hematology (Amsterdam) 1 2007 398 404
4. R.S. Komrokji, and A.F. List Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions Hematol Oncol Clin North Am 24 2010 377 388
5. Celgene Corporation Revlimid (lenalidomide) 5 mg, 10 mg, 15 mg and 25 mg capsules prescribing information USA http://www.revlimid.com/pdf/REVLIMID-PI.pdf Accessed December 2008
6. J.B. Bartlett, K. Dredge, and A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Rev Cancer 4 2004 314 322 (Pubitemid 38525287)
7. A.L. Moreira, E.P. Sampaio, A. Zmuidzinas, P. Frindt, K.A. Smith, and G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1993 1675 1680 (Pubitemid 23146134)
8. + T cells in vitro J Infect Dis 187 2003 946 955 (Pubitemid 36337907)
9. S.M. Mchugh, I.R. Rifkin, and J. Deighton The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 1995 160 167
10. K. Dredge, J.B. Marriott, and S.M. Todryk Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol (Baltimore) 168 2002 4914 4919 (Pubitemid 34495953)
11. K. Dredge, R. Horsfall, and S.P. Robinson Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res 69 2005 56 63 (Pubitemid 40410468)
12. N. Mitsiades, C.S. Mitsiades, and V. Poulaki Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 2002 4525 4530 (Pubitemid 34627223)
13. H. Geitz, S. Handt, and K. Zwingenberger Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 31 1996 213 221 (Pubitemid 26122649)
14. A. Raza, P. Meyer, and D. Dutt Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 2001 958 965
15. A. Moreno-Aspitia, G. Colon-Otero, and A. Hoering Thalidomide therapy in adult patients with myelodysplastic syndrome A North Central Cancer Treatment Group phase II trial Cancer 107 2006 767 772 (Pubitemid 44232669)
16. D. Bouscary, L. Legros, and M. Tulliez A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies Br J Haematol 131 2005 609 618 (Pubitemid 43899626)
17. P. Musto, A. Falcone, G. Sanpaolo, M. Bisceglia, R. Matera, and A.M. Carella Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes Haematologica 87 2002 884 886 (Pubitemid 34851561)
18. C. Strupp, U. Germing, M. Aivado, E. Misgeld, R. Haas, and N. Gattermann Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6 (Pubitemid 34105592)
19. C. Strupp, B. Hildebrandt, U. Germing, R. Haas, and N. Gattermann Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome Leukemia 17 2003 1200 1202 (Pubitemid 36722258)
20. A. List, S. Kurtin, and D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557 (Pubitemid 40204668)
21. A.F. List, A.F. Baker, S. Green, and W. Bellamy Lenalidomide: targeted anemia therapy for myelodysplastic syndromes Cancer Control 13 Suppl 2006 4 11 (Pubitemid 46148104)
22. H. Van Den Berghe, J.J. Cassiman, G. David, J.P. Fryns, J.L. Michaux, and G. Sokal Distinct haematological disorder with deletion of long arm of no. 5 chromosome Nature 251 1974 437 438
23. A.A. Giagounidis, U. Germing, J.S. Wainscoat, J. Boultwood, and C. Aul The 5q- syndrome Hematology (Amsterdam) 9 2004 271 277
24. + cells in patients with the 5q- syndrome Br J Haematol 139 2007 578 589 (Pubitemid 350043812)
25. T.X. Liu, M.W. Becker, and J. Jelinek Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation Nature Med 13 2007 78 83 (Pubitemid 46067389)
26. J.M. Joslin, A.A. Fernald, and T.R. Tennant Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders Blood 110 2007 719 726 (Pubitemid 47105411)
27. B.L. Ebert, J. Pretz, and J. Bosco Identification of RPS14 as a 5q- syndrome gene by RNA interference screen Nature 451 2008 335 339
28. K. Morimoto, S. Lin, and K. Sakamoto The functions of RPS19 and their relationship to Diamond-Blackfan anemia: a review Mol Genet Metab 90 2007 358 362 (Pubitemid 46505282)
29. S. Ferreira-Cerca, and E. Hurt Cell biology: arrest by ribosome Nature 459 2009 46 47
30. J.L. Barlow, L.F. Drynan, and D.R. Hewett A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome Nature Med 16 2010 59 66
31. D.T. Starczynowski, F. Kuchenbauer, and B. Argiropoulos Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype Nature Med 16 2010 49 58
32. A. List, G. Dewald, and J. Bennett Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465 (Pubitemid 44511560)
33. A. List, K. Wride, and G. Dewald Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion Leuk Res 31 Suppl 1 2007 s38
34. U. Germing, N. Gattermann, C. Strupp, M. Aivado, and C. Aul Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients Leuk Res 24 2000 983 992
35. G. Gohring, A. Giagounidis, and G. Busche Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression Ann Hematol 89 2010 365 374
36. P. Fenaux, A. Giagounidis, and D.L. Selleslag Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality J Clin Oncol (Meeting Abstracts) 28 Suppl 2010 6598
37. S. Wei, X. Chen, and K. Rocha A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide Proc Natl Acad Sci U S A 106 2009 12974 12979
38. A.F. List, K. Rocha, and L. Zhang Secondary resistance to lenalidomide in del(5q) MDS is associated with CDC25C & PP2A overexpression ASH Annual Meeting Abstracts 114 2009 292
39. A. Raza, J.A. Reeves, and E.J. Feldman Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 2008 86 93
40. L.H. Hoefsloot, M.P. Van Amelsvoort, and L.C. Broeders Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome Blood 89 1997 1690 1700 (Pubitemid 27097463)
41. + progenitor cells Cancer Res 67 2007 746 755 (Pubitemid 46192215)
42. + cells J Clin Invest 118 2008 248 258
43. B.L. Ebert, N. Galili, and P. Tamayo An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome PLoS Med 5 2008 e35
44. A.F. List, M. Estes, and A. Williams Lenalidomide (CC-5013; Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition ASH Annual Meeting Abstracts 108 2006 1360
45. A.F. List, J.E. Lancet, and M. Melchert Two-stage pharmacokinetic & efficacy study of lenalidomide alone or combined with recombinant erythropoietin (EPO) in lower risk MDS EPO-failures [PK-002] ASH Annual Meeting Abstracts 110 2007 4626
46. P.L. Greenberg, E. Attar, and M. Battiwalla Myelodysplastic syndromes J Natl Compr Cancer Netw 6 2008 902 926
47. S. Burcheri, T. Prebet, and O. Beyne-Rauzy Lenalidomide (LEN) in INT 2 and high risk MDS with DEL 5q Interim results of a phase II trial by the GFM ASH Annual Meeting Abstracts 110 2007 820
48. L. Mollgard, L. Nilsson, and L. Kjeldsen lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities ASH Annual Meeting Abstracts 114 2009 115
49. M.A. Sekeres, A.F. List, and D. Cuthbertson Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes J Clin Oncol 28 2010 2253 2258
50. R. Vij, A. Nelson, and G.L. Uy A phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old ASH Annual Meeting Abstracts 114 2009 842
51. T.A. Fehniger, J.C. Byrd, and G. Marcucci Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 Blood 113 2009 1002 1005
52. M.A. Sekeres, J.P. Maciejewski, and A.A. Giagounidis Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes J Clin Oncol 26 2008 5943 5949
53. R. Pal, S.A. Monaghan, and A.C. Hassett Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia Blood 115 2010 605 614
54. N. Chen, H. Lau, and L. Kong Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis J Clin Pharmacol 47 2007 1466 1475 (Pubitemid 350115306)